56633-71-7

Upstream product

• 186581-53-3 diazomethane 
• 61350-60-5 (S)-benzyloxycarbonyl-proline acid chloride 
• 1148-11-4 N-Benzyloxycarbonyl-L-proline 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 541-41-3 chloroformic acid ethyl ester 
• 105414-01-5 Cbz-L-Pro-OCO₂-i-Bu 

Downstream Products

• 56633-72-8 (-)-(S)-2-methoxycarbonylmethylpyrrolidine-1-carboxylic acid benzyl ester 
• 191528-61-7 Carbonic acid 2-[(S)-1-(2-azido-benzoyl)-pyrrolidin-2-yl]-ethyl ester methyl ester 
• 223785-66-8 2-(S)-(2-bromo-1-oxoethyl)pyrrolidine-1-carboxylic acid benzyl ester 
• 56633-73-9 (S)-2-(1-((benzyloxy)carbonyl)pyrrolidine-2-yl)acetic acid 
• 83455-89-4 (S)-2-Ethoxycarbonylmethyl-pyrrolidine-1-carboxylic acid benzyl ester 
• 1035279-38-9 C₃₃H₄₃N₅O₅ 
• 1035278-84-2 C₂₈H₃₅N₅O₃ 
• 1035279-34-5 C₂₅H₂₃N₃O₂ 
• 1035278-87-5 (S)-benzyl 2-(8-phenylimidazo[1,2-a]pyridin-2-yl)pyrrolidine-1-carboxylate 
• 1035279-41-4 (S)-benzyl-2-(8-bromoimidazo[1,2-a]pyridin-2-yl)pyrrolidine-1-carboxylate 
• 1035279-36-7 C₁₇H₁₇N₃ 

Relevant academic research and scientific papers

α-Xanthylmethyl Ketones from α-Diazo ketones

A simple and efficient method to obtain α-xanthylmethyl ketones from α-diazo ketones is described. The reaction proceeds through a protonation/nucleophilic substitution sequence in the presence of p -toluenesulfonic acid and potassium ethyl xanthogenate as the nucleophile. As α-diazo ketones can be readily synthesized from ubiquitous carboxylic acids, a broad variety of xanthates can be obtained, including examples from naturally occurring substrates.

INHIBITORS OF HEPATITIS C VIRUS REPLICATION

The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5A inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5A activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.

Synthesis of 2-Fluoroalkyl 4-Substituted Azepanes

Synthesis of di- and tri-substituted fluoroalkylated azepanes was achieved by ring expansion of pyrrolidines via a regioselective attack of nucleophiles on a bicyclic azetidinium intermediate. A broad scope of azepanes, substituted at C4 and bearing a α-t

Access to Enantio-enriched Substituted α-Trifluoromethyl Azepanes from l -Proline

4-Substituted α-trifluoromethyl azepanes C were synthesized via the ring expansion of trifluoromethyl pyrrolidines A, which were synthesized from l-proline via a regioselective ring-opening of a bicyclic azetidinium intermediate B by various nucleophiles.

FUSED TRICYCLIC SILYL COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES

no abstract published

Synthesis and anti-Candida activity of novel 2-hydrazino-1,3-thiazole derivatives

Eighteen new hydrazino-1,3-thiazole derivatives were evaluated against 8 strains of multi-resistant Candida spp. Introduction of an indolyl moiety linked to the hydrazone function enhanced the in vitro anti-Candida activity, with an activity spectrum towards Candida albicans strains. Introduction of a (S)-2-aminoethyl chain on the thiazole nucleus largely enhanced the in vitro antifungal activity, with a selectivity oriented towards non-C. albicans species.

FUSED TRICYCLIC COMPOUNDS AND USE THEREOF FOR TREATING VIRAL DISEASES

Fused tricyclic compounds of formula (I) and pharmaceutically acceptable salts thereof are disclosed, wherein X1, X2, X3, X4, Y1, Y2, M1, M2, Ra, Rb, R1, R2 and R6 are as defined in the description. Compositions comprising at least one fused tricyclic compound and methods of using the fused tricyclic compounds for treating or preventing HCV infection in a patient are also disclosed.

TETRACYCLIC HETEROCYCLE COMPOUNDS FOR TREATING HEPATITIS C VIRAL INFECTION

Tetracyclic heterocycle compounds of formula (I) and pharmaceutically acceptable salts thereof are provided, wherein A, A', G, R1, R15, U, V, V', W, W, X, X', Y and Y' are as defined in the invention. The pharmaceutical compositions comprising these compounds and the use of the compounds for treating hepatitis C virus (HCV) infection are also provided.

TETRACYCLIC INDOLE DERIVATIVES FOR TREATING HEPATITIS C VIRUS INFECTION

Tetracyclic indole derivatives of formula (I), pharmaceutically acceptable salts and the pharmaceutical compositions thereof are provided, wherein A, A', G, R1, R15, U, V, V, W, W, X, X', Y, Y' are as defined in the invention. Use of these derivatives for treating hepatitis C virus (HCV) infection is also provided.

TETRACYCLIC INDOLE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES

The present invention relates to novel Tetracyclic Indole Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, A', G, R1, R15, U, V, V', X, X', Y and Y' are as defined herein. The present invention also relates to compositions comprisingat least one Tetracyclic Indole Derivative, and methods of using the Tetracyclic Indole Derivatives for treating or preventing HCV infection in a patient.